CD317-Positive Immune Stromal Cells in Human "Mesenchymal Stem Cell" Populations

• Published in: Frontiers in immunology Vol. 13; p. 903796
• Main Authors: Kay, Alasdair G, Fox, James M, Hewitson, James P, Stone, Andrew P, Robertson, Sophie, James, Sally, Wang, Xiao-Nong, Kapasa, Elizabeth, Yang, Xuebin B, Genever, Paul G
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06-06-2022
• Subjects: Animals; BST2; CD317; heterogeneity; Humans; Immunology; immunomodulation; Mesenchymal Stem Cells - metabolism; mesenchymal stromal cells; Mice; MSC subtypes; Signal Transduction; Stromal Cells; Th1 Cells; BST2; immunomodulation; CD317; mesenchymal stromal cells; MSC subtypes; heterogeneity; tetherin
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.903796

Heterogeneity of bone marrow mesenchymal stromal cells (MSCs, frequently referred to as "mesenchymal stem cells") clouds biological understanding and hampers their clinical development. In MSC cultures most commonly used in research and therapy, we have identified an MSC subtype characterized by CD317 expression (CD317
(29.77 ± 3.00% of the total MSC population), comprising CD317
(28.10 ± 4.60%) and CD317
(1.67 ± 0.58%) MSCs) and a constitutive interferon signature linked to human disease. We demonstrate that CD317
MSCs induced cutaneous tissue damage when applied a skin explant model of inflammation, whereas CD317
MSCs had no effect. Only CD317
MSCs were able to suppress proliferative cycles of activated human T cells
, whilst CD317
MSCs increased polarization towards pro-inflammatory Th1 cells and CD317
cell lines did not. Using an
peritonitis model, we found that CD317
and CD317
MSCs suppressed leukocyte recruitment but only CD317
MSCs suppressed macrophage numbers. Using MSC-loaded scaffolds implanted subcutaneously in immunocompromised mice we were able to observe tissue generation and blood vessel formation with CD317
MSC lines, but not CD317
MSC lines. Our evidence is consistent with the identification of an immune stromal cell, which is likely to contribute to specific physiological and pathological functions and influence clinical outcome of therapeutic MSCs.